<DOC>
	<DOCNO>NCT00865293</DOCNO>
	<brief_summary>The purpose study investigate posture dependent small airway obstruction subject obesity , study capacity FOT measurement tool small airway obstruction .</brief_summary>
	<brief_title>Expiratory Airflow Limitation Subjects With Obesity</brief_title>
	<detailed_description>Obesity cause dyspnea due mechanical impairment pulmonary ventilation . One cause impairment expiratory flow limitation , relate decreased lung volume . As result , obesity cause asthma-like symptom . Therefore , patient obesity misdiagnosed asthma-patients , treat asthma medication . The effect bronchodilator mechanical airway obstruction obese subject well establish . Posture also effect lung volume : decrease supine position . Therefore , interaction obesity supine posture might result large decrease lung volume , thereby increase airflow limitation . It suggest obesity supine posture result obstruction peripheral airway . Such obstruction measure spirometry , use ratio force expiratory flow 25 75 % vital capacity . This measure highly variable , however . The forced oscillation technique ( FOT ) non-invasive method measure resistance reactant respiratory system . Particularly reactance show useful measurement airflow limitation . The investigator hypothesize obesity cause posture dependent end- expiratory airflow limitation due mechanical compression lung tissue , result increase resistance reactance airway . Therefore , investigator expect protective effect bronchodilation salbutamol . The investigator expect reactance measure FOT detects difference airflow limitation correlate airflow limitation measure spirometry .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>Inclusion Criteria obese population : Male/female , age 2560 BMI ( body mass index ) 3040 kg/m2 Non ex smoker &lt; 10 packyears Inclusion Criteria control population : Male/female , age 2560 BMI ( body mass index ) 18.525 kg/m2 Non ex smoker &lt; 10 packyears Exclusion Criteria obese population : Asthma COPD ( FEV1/FVC &lt; 0.70 ) Reversibility &gt; 9 % FEV1 ( 400 microgram salbutamol ) Other significant neuromuscular , cardiac lung disease Exclusion Criteria control population : Asthma COPD ( FEV1/FVC &lt; 0.70 ) Other significant neuromuscular , cardiac lung disease Reversibility &gt; 9 % FEV1 ( 400 microgram salbutamol )</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Obesity</keyword>
	<keyword>expiratory flow limitation</keyword>
	<keyword>EFL</keyword>
	<keyword>posture</keyword>
	<keyword>small airway obstruction</keyword>
	<keyword>FOT</keyword>
</DOC>